Treatment Options for Anemia in Kidney Transplant Patients: A Review

Bonomini, Mario; Liberato, Lorenzo Di; Sirolli, Vittorio

doi:10.1016/j.xkme.2023.100681

Cited by 5 publications

(1 citation statement)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A substantial number of kidney transplant recipients develop anemia at various time points after transplantation, with a prevalence of ∼50% during the first six months that decreases to 23–35% in later stages [ 65 ]. Multi-factorial risk factors of post-transplant anemia include impaired graft function, iron deficiency, female gender, use of angiotensin-converting enzyme inhibitors, antibiotics, antiviral and immunosuppressive treatment and inflammation [ 65 ]. Kidney transplant recipients might present high levels of inflammation thus resulting hyporesponsive to ESAs.…”

Section: Use Of Hif-phis In Subpopulations Of Interestmentioning

confidence: 99%

Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease

Locatelli,

Del Vecchio,

Esposito

et al. 2024

J Nephrol

View full text Add to dashboard Cite

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new drugs developed for the treatment of anemia associated with chronic kidney disease (CKD). This class of drugs stimulates endogenous erythropoietin production and, at the same time, improves iron absorption and mobilization of iron stores (less evident with daprodustat, vadadustat and enarodustat). Several studies have been published in the last few years showing that these agents are not inferior to standard therapy in correcting anemia associated with CKD. The efficacy of HIF-PHIs is coupled with a safety profile comparable to that of standard erythropoiesis stimulating agent (ESA) treatment. However, studies with HIF-PHIs were not long enough to definitively exclude the impact of new drugs on adverse events, such as cancer, death and possibly cardiovascular events, that usually occur after a long follow-up period. Kidney Disease: Improving Global Outcomes (KDIGO) recently reported the conclusions of the Controversies Conference on HIF-PHIs held in 2021. The goal of the present position paper endorsed by the Italian Society of Nephrology is to better adapt the conclusions of the latest KDIGO Conference on HIF-PHIs to the Italian context by reviewing the efficacy and safety of HIF-PHIs as well as their use in subpopulations of interest as emerged from more recent publications not discussed during the KDIGO Conference. Graphical abstract

show abstract

Section: Use Of Hif-phis In Subpopulations Of Interestmentioning

confidence: 99%

Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease

Locatelli,

Del Vecchio,

Esposito

et al. 2024

J Nephrol

View full text Add to dashboard Cite

show abstract

Transfusion-induced HLA sensitization in wait-list patients and kidney transplant recipients

Willicombe,

Roberts

2024

Kidney International

View full text Add to dashboard Cite

Epos EPO

Naas,

Schödel,

Grampp

2024

Nephrologie aktuell

View full text Add to dashboard Cite

ZUSAMMENFASSUNGDie Substitution des Hormons Erythropoetin (EPO) stellte bisher den Grundpfeiler der Therapie der renalen Anämie bei nierenkranken Patienten*innen dar. Die seit über 30 Jahren in der Praxis etablierte Anwendung macht die verwendeten rekombinanten Substanzen zu Medikamenten, für die ein reicher Erfahrungsschatz vorliegt. Aufgrund seiner umschriebenen Wirkweise, des bekannten Nebenwirkungsprofils sowie der aktuellen Studienlage, die bisher überwiegend eine Gleichwertigkeit gegenüber neuen Erythropoese stimulierenden Agenzien (ESA) zeigt, ist wohl kein Ende der EPO-Substitutionstherapie abzusehen. Die Therapie der renalen Anämie wird allerdings durch neue Erkenntnisse zum Eisenhaushalt sowie die nun zugelassenen HIF-Stabilisatoren optimiert und individualisiert werden können.

show abstract

Treatment Options for Anemia in Kidney Transplant Patients: A Review

Cited by 5 publications

References 89 publications

Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease

Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease

Transfusion-induced HLA sensitization in wait-list patients and kidney transplant recipients

Epos EPO

Contact Info

Product

Resources

About